# Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease

> **NCT04325893** · PHASE3 · TERMINATED · sponsor: **University Hospital, Angers** · enrollment: 259 (actual)

## Conditions studied

- Coronavirus

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04325893
- **Lead sponsor:** University Hospital, Angers
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-01
- **Primary completion:** 2020-06-18
- **Final completion:** 2020-06-18
- **Target enrollment:** 259 (ACTUAL)
- **Why stopped:** decrease in number of eligible patients
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325893, "Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04325893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*